Education
About Us
Working with TipRanks
Follow Us
Opus Genetics (IRD)
NASDAQ:IRD
IRD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.81 - $2.51
Previous CloseN/A
Volume154.21K
Average Volume (3M)149.57K
Market Cap
$32.52M
Enterprise Value-$2.38M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)0.00
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Mar 06, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding31,568,457
10 Day Avg. Volume155,952
30 Day Avg. Volume149,573
Standard Deviation0.20
R-Squared0.00183
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.88
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.50Price Target Upside725.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Opus Genetics News
PremiumCompany Announcements
Opus Genetics Enhances Executive Severance Packages
---
Bulls Say, Bears Say
Bulls Say
Clinical DataInitial positive signals in more advanced non-pediatric patients demonstrate visual acuity gains and safe delivery, which bodes well for translatability to forthcoming pediatric data.
Regulatory ProspectsRegulators seem open to novel endpoints, which bodes well for OPGx-LCA5 regulatory prospects.
Bears Say
Market AdoptionSome investors believe that a new therapy will need to show significant vision improvement (and not just prevention of worsening) to garner adoption.
---
Ownership Overview
7.74% Insiders
4.40% Mutual Funds
10.12% Other Institutional Investors
74.36% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
IRD FAQ
What was Opus Genetics’s price range in the past 12 months?
Opus Genetics lowest stock price was $0.81 and its highest was $2.51 in the past 12 months.
What is Opus Genetics’s market cap?
Opus Genetics’s market cap is $32.52M.
When is Opus Genetics’s upcoming earnings report date?
Opus Genetics’s upcoming earnings report date is Mar 06, 2025 which is in 2 days.
How were Opus Genetics’s earnings last quarter?
Opus Genetics released its earnings results on Nov 12, 2024. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.238 by -$0.052.
Is Opus Genetics overvalued?
According to Wall Street analysts Opus Genetics’s price is currently Undervalued.
Does Opus Genetics pay dividends?
Opus Genetics does not currently pay dividends.
What is Opus Genetics’s EPS estimate?
Opus Genetics’s EPS estimate is 0.02.
How many shares outstanding does Opus Genetics have?
Opus Genetics has 31,568,457 shares outstanding.
What happened to Opus Genetics’s price movement after its last earnings report?
Opus Genetics reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.238. Following the earnings report the stock price went down -2.564%.
Which hedge fund is a major shareholder of Opus Genetics?
Currently, no hedge funds are holding shares in IRD
---
Opus Genetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (725.24% Upside)
$8.50 (725.24% Upside)
Blogger Sentiment
Bullish
IRD Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $97.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.23%
12-Months-Change
Fundamentals
Return on Equity
-64.30%
Trailing 12-Months
Asset Growth
-25.47%
Trailing 12-Months
Company Description
Opus Genetics
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.
---
IRD Stock 12 Month Forecast
Average Price Target
$8.50
▲(725.24% Upside)
Technical Analysis
Best Analysts Covering IRD
1 Year
1 Year Success Rate
6/21 ratings generated profit
1 Year Average Return
-4.71%
reiterated a buy rating 14 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -4.71% per trade.
---